Thyroid Drugs Part 2 PDF

\#\#\# \*\*Slide 7: Levothyroxine (T4)\*\* 1\. \*\*Levothyroxine is the treatment of choice for which condition?\*\* \- A. Hyperthyroidism \- B. Hypothyroidism \- C. Thyroid storm \- D. Goiter \*\*Answer:\*\* B. Hypothyroidism 2\. \*\*What is the primary reason levothyroxine should be taken o...

\#\#\# \*\*Slide 7: Levothyroxine (T4)\*\* 1\. \*\*Levothyroxine is the treatment of choice for which condition?\*\* \- A. Hyperthyroidism \- B. Hypothyroidism \- C. Thyroid storm \- D. Goiter \*\*Answer:\*\* B. Hypothyroidism 2\. \*\*What is the primary reason levothyroxine should be taken on an empty stomach?\*\* \- A. To enhance its metabolism \- B. To prevent gastrointestinal side effects \- C. To optimize its absorption \- D. To increase its half-life \*\*Answer:\*\* C. To optimize its absorption 3\. \*\*Which of the following is a boxed warning associated with levothyroxine?\*\* \- A. Risk of thyroid storm \- B. Increased risk of osteoporosis \- C. Not for use in the treatment of obesity or weight loss \- D. Risk of severe liver injury \*\*Answer:\*\* C. Not for use in the treatment of obesity or weight loss \-\-- \#\#\# \*\*Slide 8: Monitoring Levothyroxine Therapy\*\* 1\. \*\*When should a full thyroid panel be repeated after starting or changing the dose of levothyroxine?\*\* \- A. After 2 weeks \- B. After 4-6 weeks \- C. After 6-8 weeks \- D. After 3 months \*\*Answer:\*\* C. After 6-8 weeks 2\. \*\*Which laboratory test is considered the most sensitive for monitoring levothyroxine therapy in hypothyroid patients?\*\* \- A. Free T3 \- B. Total T4 \- C. TSH (Thyroid Stimulating Hormone) \- D. Reverse T3 \*\*Answer:\*\* C. TSH 3\. \*\*Levothyroxine dosing for adults is typically initiated at:\*\* \- A. 1.6 mcg/kg/day \- B. 0.8 mcg/kg/day \- C. 2.5 mcg/kg/day \- D. 0.5 mcg/kg/day \*\*Answer:\*\* A. 1.6 mcg/kg/day \-\-- \#\#\# \*\*Slide 9: Thyroid Function Tests\*\* 1\. \*\*Which thyroid function test helps assess the brain's perception of thyroid hormone status?\*\* \- A. Free T3 \- B. Free T4 \- C. TSH \- D. Reverse T3 \*\*Answer:\*\* C. TSH 2\. \*\*What role does reverse T3 (rT3) play in thyroid hormone metabolism?\*\* \- A. It is the biologically active form of T3 \- B. It is an inactive form of T3 produced during illness or stress \- C. It enhances the action of T4 \- D. It stimulates thyroid hormone production \*\*Answer:\*\* B. It is an inactive form of T3 produced during illness or stress 3\. \*\*Which of the following can promote the conversion of T4 to rT3?\*\* \- A. Chronic inflammation \- B. Hypercalcemia \- C. High serum sodium levels \- D. Low cholesterol \*\*Answer:\*\* A. Chronic inflammation \-\-- \#\#\# \*\*Slide 10: Intracellular Action of Thyroid Hormones\*\* 1\. \*\*Which enzyme is responsible for converting T4 to the active form T3 within cells?\*\* \- A. Thyroid peroxidase \- B. D1 and D2 deiodinases \- C. Amylase \- D. Lipase \*\*Answer:\*\* B. D1 and D2 deiodinases 2\. \*\*What happens to T3 production during periods of acute illness or inflammation?\*\* \- A. It increases dramatically \- B. It remains unchanged \- C. It decreases due to increased rT3 production \- D. It is enhanced by increased D2 enzyme activity \*\*Answer:\*\* C. It decreases due to increased rT3 production 3\. \*\*Why can T3 production not always be assessed using standard lab tests during illness?\*\* \- A. T3 production is primarily extracellular \- B. Intracellular T3 production is impaired but not extracellular T3 \- C. Labs only measure the inactive form rT3 \- D. The body stops producing T3 entirely \*\*Answer:\*\* B. Intracellular T3 production is impaired but not extracellular T3 \-\-- \#\#\# \*\*Slide 11: Goals of Hypothyroidism Therapy\*\* 1\. \*\*What is the primary goal of levothyroxine therapy in hypothyroidism?\*\* \- A. Reduce thyroid gland size \- B. Normalize TSH secretion \- C. Increase T3 levels \- D. Prevent goiter formation \*\*Answer:\*\* B. Normalize TSH secretion 2\. \*\*In patients with goiter, levothyroxine therapy aims to:\*\* \- A. Increase T4 synthesis \- B. Reduce the size of the goiter \- C. Stimulate TSH release \- D. Increase iodine uptake \*\*Answer:\*\* B. Reduce the size of the goiter 3\. \*\*What is the recommended target range for TSH in patients receiving levothyroxine replacement therapy?\*\* \- A. 0.1-0.5 µU/ml \- B. 0.5-2.5 µU/ml \- C. 2.5-5.0 µU/ml \- D. 3.0-6.0 µU/ml \*\*Answer:\*\* B. 0.5-2.5 µU/ml \-\-- \#\#\# \*\*Slide 12: Hypothyroid Therapy in Special Populations\*\* 1\. \*\*Which population requires a lower initial dose of levothyroxine to avoid overtreatment?\*\* \- A. Pregnant women \- B. Children \- C. Elderly patients with cardiovascular disease \- D. Athletes \*\*Answer:\*\* C. Elderly patients with cardiovascular disease 2\. \*\*Why should pregnant women with hypothyroidism be monitored more frequently during treatment?\*\* \- A. To avoid excessive T3 production \- B. Because thyroid hormone demands increase during pregnancy \- C. To ensure the baby is not affected by high T4 levels \- D. Due to the risk of hyperglycemia \*\*Answer:\*\* B. Because thyroid hormone demands increase during pregnancy 3\. \*\*Which of the following is a common risk of undertreating hypothyroidism during pregnancy?\*\* \- A. Premature labor \- B. Fetal hyperthyroidism \- C. Gestational diabetes \- D. Fetal developmental delays \*\*Answer:\*\* D. Fetal developmental delays